Search: onr:"swepub:oai:gup.ub.gu.se/127144" >
Biomarkers for Alzh...
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.
-
Hampel, Harald (author)
-
Frank, Richard (author)
-
Broich, Karl (author)
-
show more...
-
Teipel, Stefan J (author)
-
Katz, Russell G (author)
-
Hardy, John (author)
-
Herholz, Karl (author)
-
Bokde, Arun L W (author)
-
Jessen, Frank (author)
-
Hoessler, Yvonne C (author)
-
Sanhai, Wendy R (author)
-
- Zetterberg, Henrik, 1973 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
Woodcock, Janet (author)
-
- Blennow, Kaj, 1958 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
show less...
-
(creator_code:org_t)
- Springer Science and Business Media LLC, 2010
- 2010
- English.
-
In: Nature reviews. Drug discovery. - : Springer Science and Business Media LLC. - 1474-1784 .- 1474-1776. ; 9:7, s. 560-74
- Related links:
-
https://gup.ub.gu.se...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Advances in therapeutic strategies for Alzheimer's disease that lead to even small delays in onset and progression of the condition would significantly reduce the global burden of the disease. To effectively test compounds for Alzheimer's disease and bring therapy to individuals as early as possible there is an urgent need for collaboration between academic institutions, industry and regulatory organizations for the establishment of standards and networks for the identification and qualification of biological marker candidates. Biomarkers are needed to monitor drug safety, to identify individuals who are most likely to respond to specific treatments, to stratify presymptomatic patients and to quantify the benefits of treatments. Biomarkers that achieve these characteristics should enable objective business decisions in portfolio management and facilitate regulatory approval of new therapies.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Psykiatri (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Psychiatry (hsv//eng)
Keyword
- Alzheimer Disease
- diagnosis
- genetics
- Animals
- Biological Markers
- Clinical Trials as Topic
- Drug Discovery
- legislation & jurisprudence
- trends
- Drug Industry
- trends
- Endpoint Determination
- Humans
- Magnetic Resonance Imaging
- Molecular Biology
- Positron-Emission Tomography
- Risk Assessment
Publication and Content Type
- ref (subject category)
- for (subject category)
Find in a library
To the university's database
- By the author/editor
-
Hampel, Harald
-
Frank, Richard
-
Broich, Karl
-
Teipel, Stefan J
-
Katz, Russell G
-
Hardy, John
-
show more...
-
Herholz, Karl
-
Bokde, Arun L W
-
Jessen, Frank
-
Hoessler, Yvonne ...
-
Sanhai, Wendy R
-
Zetterberg, Henr ...
-
Woodcock, Janet
-
Blennow, Kaj, 19 ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Psychiatry
- Articles in the publication
-
Nature reviews. ...
- By the university
-
University of Gothenburg